Shire plc (SHPG) Tops Q4 EPS by 8c, Provides Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Shire (SHPG) is Not a Compelling Growth Story - Piper Jaffray
February 12, 2016 8:16 AM ESTPiper Jaffray analyst, David Amsellem, thinks Shire (NASDAQ: SHPG) does not represent a compelling growth story despite a number of regulatory catalysts in 2016. He reduced his PT to $175 from $219 and maintained his Neutral rating.
Shire reported 4Q15 non-GAAP EPS of $2.97 on revenues of $1.7B, versus the Street estimates of $2.87 and $1.7B, respectively. Vyvanse and Lialda were key bright spots, though these are also the products that likely have the shortest-lived durability in the combined SHPG/Baxalta portfolio (patent expiries in 2023 and... More



